^
    1d
    SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC. (PubMed, Future Oncol)
    www.clinicaltrials.gov identifier is NCT06119581. EudraCT: 2023-503412-33-00.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • olomorasib (LY3537982)
    4d
    Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy. (PubMed, Radiother Oncol)
    Toxicity included 13 grade 2 events (31%) and one grade 3 pneumonitis-with no significant differences between patients who held or continued inhibitors during radiotherapy. Estimated 6-month cumulative incidence of local failure was 5%.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Lumakras (sotorasib) • Krazati (adagrasib)
    4d
    Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Nov 2026 | Trial primary completion date: Mar 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • carfilzomib
    5d
    Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. (PubMed, Lancet Oncol)
    In treatment-naive KRASG12C-mutated NSCLC, fulzerasib plus cetuximab showed encouraging activity with a favourable safety profile. The combination is currently being planned for investigation in a phase 3 study.
    P1/2 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • Dupert (fulzerasib)
    6d
    Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers (clinicaltrials.gov)
    P1, N=52, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2030 --> Dec 2026
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • KEAP1 (Kelch Like ECH Associated Protein 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    KRAS mutation • KRAS G12C • KEAP1 mutation • KRAS G12
    |
    Lynparza (olaparib) • Krazati (adagrasib)
    6d
    KANDLELIT-013: MK-3475A±MK-1084 in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) (clinicaltrials.gov)
    P3, N=400, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • calderasib (MK-1084)
    6d
    Advancements in Sotorasib: A Comprehensive Review of its Efficacy in Non-small Lung Cancer Treatment. (PubMed, Recent Pat Anticancer Drug Discov)
    This review also highlights the drug's synthetic processes, structural features, and global patent coverage. SR approval marks a significant milestone in KRAS-targeted therapies, offering new hope for patients with difficult-to-treat lung cancer.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Lumakras (sotorasib)
    7d
    Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report. (PubMed, Front Oncol)
    This case highlights the potential of sotorasib in combination regimens as a first-line treatment strategy for KRAS G12C-mutated NSCLC and underscores the importance of individualized treatment planning. However, the use of sotorasib in the first-line setting remains an exploratory off-label approach and requires further clinical evidence to validate this treatment strategy.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12
    |
    Lumakras (sotorasib)
    7d
    KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (clinicaltrials.gov)
    P2, N=130, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed • calderasib (MK-1084)
    11d
    A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation (clinicaltrials.gov)
    P2, N=14, Recruiting, Amgen
    Trial initiation date
    |
    Vectibix (panitumumab) • Lumakras (sotorasib)
    11d
    Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). (clinicaltrials.gov)
    P3, N=345, Active, not recruiting, Amgen | Trial completion date: Feb 2026 --> May 2026
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    docetaxel • Lumakras (sotorasib)
    11d
    Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, Mirati Therapeutics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib)